Callio Therapeutics develops multi-payload antibody-drug conjugates for cancer therapy.

AnaCardio is a biopharmaceutical company developing an oral ghrelin receptor agonist to treat heart failure with reduced ejection fraction.

Citryll is a biotech company developing therapies for immune-mediated inflammatory diseases, focusing on a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs).

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Memo Therapeutics is a late-stage biotech company that has raised CHF 25M in a Series C funding round to develop its antibody, AntiBKV, and advance its existing antibody pipeline.

MinervaX is a Danish biotechnology company that has raised EUR 54 million to advance the development of its maternal vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns.